

Non-invasive and targeted transcranial focused ultrasound (FUS) treatments combined with systemically administered microbubbles enhance the delivered chemotherapeutic dose within brain tumours, due to reversible blood–brain barrier opening (BBBO).1–3 In preclinical studies, increased drug delivery has led to measurable overall survival benefit in animal models of high-grade glioma.4–7 However, to date, there has been no evidence of prolonged overall survival in individuals with glioma.
Oncology
|31st Dec, 2025
|Journal of the American Medical Association
Oncology
|15th Jan, 2026
|The Lancet
Oncology
|15th Jan, 2026
|The Lancet
Oncology
|15th Jan, 2026
|The Lancet
Oncology
|15th Jan, 2026
|The Lancet
Oncology
|15th Jan, 2026
|The Lancet
Oncology
|15th Jan, 2026
|The Lancet